CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-18 | van Houte Hans Chief Financial Officer | Sale | −3,140 | $34.24 | $108K | 10,443 |
| 2021-02-18 | van Houte Hans Chief Financial Officer | Sale | −3,652 | $35.10 | $128K | 6,791 |
| 2021-02-18 | van Houte Hans Chief Financial Officer | Sale | −5,725 | $36.00 | $206K | 1,066 |
| 2021-02-18 | van Houte Hans Chief Financial Officer | Sale | −666 | $36.91 | $25K | 400 |
| 2021-02-18 | van Houte Hans Chief Financial Officer | Sale | −400 | $38.05 | $15K | 0 |
| 2021-02-18 | van Houte Hans Chief Financial Officer | Exercise or conversion · Employee Stock Option (right to buy) | −13,583 | 69,750 | ||
| 2021-02-18 | Ring Christine General Counsel | Exercise or conversion | +2,000 | $1.86 | $4K | 2,000 |
| 2021-02-18 | Ring Christine General Counsel | Sale | −400 | $34.48 | $14K | 1,600 |
| 2021-02-18 | Ring Christine General Counsel | Sale | −1,100 | $35.86 | $39K | 500 |
| 2021-02-18 | Ring Christine General Counsel | Sale | −500 | $37.03 | $19K | 0 |
| 2021-02-18 | Ring Christine General Counsel | Exercise or conversion · Employee Stock Option (right to buy) | −2,000 | 119,666 | ||
| 2021-02-18 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +800 | $7.26 | $6K | 12,800 |
| 2021-02-18 | Hansen Gwenn Chief Scientific Officer | Sale | −600 | $35.81 | $21K | 12,200 |
| 2021-02-18 | Hansen Gwenn Chief Scientific Officer | Sale | −200 | $37.67 | $8K | 12,000 |
| 2021-02-18 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −800 | 75,866 | ||
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +9,107 | $0.84 | $8K | 9,107 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +3,797 | $7.26 | $28K | 12,904 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +2,096 | $9.57 | $20K | 15,000 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Sale | −2,647 | $34.19 | $90K | 12,353 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Sale | −4,553 | $35.02 | $159K | 7,800 |
Page 39 of 42 · 829 trades